Impact of enzymatic digestion on bacterial community composition in CF airway samples

Kayla M. Williamson 1, Brandie D. Wagner Corresp. 1, 2, Charles E. Robertson 3, Emily J. Johnson 2, 4, Edith T. Zemanick 2, J. Kirk Harris 2

1 Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado at Denver, Aurora, Colorado, United States
2 Department of Pediatrics, School of Medicine, University of Colorado at Denver, Aurora, Colorado, United States
3 Division of Infectious Diseases, School of Medicine, University of Colorado at Denver, Aurora, Colorado, United States
4 Multicare Tacoma Family Medicine, Tacoma, Washington, United States

Corresponding Author: Brandie D. Wagner
Email address: brandie.wagner@ucdenver.edu

Background. Previous studies have demonstrated the importance of DNA extraction methods for molecular detection of Staphylococcus, an important bacterial group in cystic fibrosis (CF). We sought to evaluate the effect of enzymatic digestion (EnzD) prior to DNA extraction on bacterial communities identified in sputum and oropharyngeal swab (OP) samples from patients with CF. Methods. DNA from 81 samples (39 sputum and 42 OP) collected from 63 patients with CF was extracted in duplicate with and without EnzD. Bacterial communities were determined by rRNA gene sequencing, and measures of alpha and beta diversity were calculated. Principal Coordinate Analysis (PCoA) was used to assess differences at the community level and Wilcoxon Signed Rank tests were used to compare relative abundance (RA) of individual genera for paired samples with and without EnzD. Results. Shannon Diversity Index (alpha-diversity) decreased in sputum and OP samples with the use of EnzD. Larger shifts in community composition were observed for OP samples (beta-diversity, measured by Morisita-Horn), whereas less change in communities was observed for sputum samples. The use of EnzD with OP swabs resulted in significant increase in RA for the genera Gemella (p < 0.01), Streptococcus (p < 0.01), and Rothia (p < 0.01). Staphylococcus (p<0.01) was the only genus with a significant increase in RA from sputum, whereas the following genera decreased in RA with EnzD: Veillonella (p<0.01), Granulicatella (p<0.01), Prevotella (p<0.01), and Gemella (p=0.02). In OP samples, higher RA of Gram-positive taxa was associated with larger changes in microbial community composition. Discussion. We show that the application of EnzD to CF airway samples, particularly OP swabs, results in differences in microbial communities detected by sequencing. Use of EnzD can result in large changes in bacterial community composition, and is particularly useful for detection of Staphylococcus in CF OP samples. The enhanced identification of Staphylococcus aureus is a strong indication...
to utilize EnzD in studies that use OP swabs to monitor CF airway communities.
Impact of enzymatic digestion on bacterial community composition in CF airway samples

Kayla M. Williamson¹, Brandie D. Wagner¹,², Charles E. Robertson³, Emily J. Johnson²*, Edith T. Zemanick², and J. Kirk Harris²

¹Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado School of Medicine, Aurora, Colorado, United States of America

²Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, United States of America

³Division of Infectious Diseases, University of Colorado, School of Medicine, Aurora, Colorado, United States of America

*Current Address: Multicare Tacoma Family Medicine, Tacoma, Washington, United States of America

Corresponding author:

Brandie Wagner

Email: brandie.wagner@ucdenver.edu
Abstract

Background. Previous studies have demonstrated the importance of DNA extraction methods for molecular detection of *Staphylococcus*, an important bacterial group in cystic fibrosis (CF). We sought to evaluate the effect of enzymatic digestion (EnzD) prior to DNA extraction on bacterial communities identified in sputum and oropharyngeal swab (OP) samples from patients with CF.

Methods. DNA from 81 samples (39 sputum and 42 OP) collected from 63 patients with CF was extracted in duplicate with and without EnzD. Bacterial communities were determined by rRNA gene sequencing, and measures of alpha and beta diversity were calculated. Principal Coordinate Analysis (PCoA) was used to assess differences at the community level and Wilcoxon Signed Rank tests were used to compare relative abundance (RA) of individual genera for paired samples with and without EnzD.

Results. Shannon Diversity Index (alpha-diversity) decreased in sputum and OP samples with the use of EnzD. Larger shifts in community composition were observed for OP samples (beta-diversity, measured by Morisita-Horn), whereas less change in communities was observed for sputum samples. The use of EnzD with OP swabs resulted in significant increase in RA for the genera *Gemella* (*p* < 0.01), *Streptococcus* (*p* < 0.01), and *Rothia* (*p* < 0.01). *Staphylococcus* (*p* < 0.01) was the only genus with a significant increase in RA from sputum, whereas the following genera decreased in RA with EnzD: *Veillonella* (*p* < 0.01), *Granulicatella* (*p* < 0.01), *Prevotella* (*p* < 0.01), and *Gemella* (*p* = 0.02). In OP samples, higher RA of Gram-positive taxa was associated with larger changes in microbial community composition.

Discussion. We show that the application of EnzD to CF airway samples, particularly OP swabs, results in differences in microbial communities detected by sequencing. Use of EnzD can result
in large changes in bacterial community composition, and is particularly useful for detection of

*Staphylococcus* in CF OP samples. The enhanced identification of *Staphylococcus aureus* is a

strong indication to utilize EnzD in studies that use OP swabs to monitor CF airway

communities.
Introduction

Cystic Fibrosis (CF) is an autosomal recessive disease, characterized by chronic airway infection, whose predominant pathogens include *Staphylococcus aureus*, *Pseudomonas aeruginosa* and other Gram-negative bacteria (Heijerman, 2005; LiPuma, 2010). OP swabs are commonly used when children are unable to expectorate (Zemanick et al., 2015). This is particularly true for pediatric, non-expectorating subjects with CF in whom oropharyngeal (OP) cultures are used as a surrogate for lower airway bacteria. (Zemanick et al., 2015). In the pediatric studies, OP swabs have ranged from 30% to 68% of samples collected (Armstrong et al., 1996; Zemanick et al., 2010; Wolter et al., 2013; Hoppe et al., 2015) and therefore represent an important sample type in early CF.

Sequencing is becoming more widely used to evaluate bacterial communities in CF airway samples (Cummings et al., 2016). DNA preparation prior to sequencing, including cell lysis, can have a profound effect on microbial community composition especially in detecting certain organisms such as *S. aureus* (Zhao et al., 2012; Yuan et al., 2012b; Willner et al., 2012; Lozupone et al., 2013; Pérez-losada, Crandall & Freishtat, 2016). *S. aureus* in particular has a rigid cell wall that can be hard to rupture, hindering the ability to efficiently extract DNA for molecular detection (Zhao et al., 2012).

Previous studies have indicated that use of enzymatic digestion (EnzD) may enhance the ability to detect *Staphylococcus* (Schindler & Schuhardt, 1964; Browder et al., 1965; Yuan et al., 2012a; Zhao et al., 2012; Johnson et al., 2016). Specifically, Yuan et al (2012) performed a comprehensive experiment evaluating multiple DNA extraction methods utilizing human associated bacterial species as well as a mock community. Zhao et al. (2012) found that EnzD increased the yield of *Staphylococcus* in sputum samples. Similarly, Johnson et al (2016)
determined EnzD improved the sensitivity of sequencing in OP swabs while no differences were observed in sputum samples. Increased sensitivity with EnzD was robust when compared to clinical culture results and qPCR. Furthermore, the work showed that the majority of *Staphylococcus* was *S. aureus*. It remains unclear, however, how the use of EnzD effects the remaining bacterial community in clinical CF samples. In this work, we build on these two previous CF studies to evaluate the effect of DNA extraction using enzymatic digestion (EnzD) on bacterial communities detected from oropharyngeal swab (OP) and sputum samples collected from patients with CF.

**Materials & Methods**

**Patient demographics and samples.** Sputum and OP samples were obtained from patients with CF as part of standard of care for monitoring bacterial infection during routine patient visits. Further explanation of selection of samples to be used for this study are included in a previous publication (Johnson et al., 2016). Excess specimen was stored frozen at -80 °C for molecular assessment of infection. Standard sputum processing protocol was performed for sample homogenization utilizing sputalysin and standard CF culture was performed following CF Foundation guidelines (Burns et al., 1998). The Colorado Multiple Institutional Review Board approved the study (COMIRB 07-0835). Written informed consent was obtained from patients or guardians. Written informed assent was obtained for children 10-17 years of age.

**DNA extraction methods.** DNA was extracted using the Qiagen EZ1 Advanced automated extraction platform using the Tissue kit and bacterial card per manufacturer’s instructions. EnzD was performed on one replicate of each sample by mixing with lysostaphin (final concentration
0.18 mg/mL) and lysozyme (3.6 mg/mL) and incubated at 37°C for 30 minutes. Samples were then digested with proteinase K (1.4 mg/mL) and incubated at 65°C for ten minutes, then incubated at 95°C for 10 minutes. (Zhao et al., 2012; Johnson et al., 2016). Lysozyme and lysostaphin target degradation of the bacterial cell wall by targeting peptidoglycan (lysozyme) and pentaglycine bridges (lysostaphin) (Salazar & Asenjo, 2007). Lysostaphin is specific to the subset of staphylococci that contain pentaglycine bridges including the human pathogen S. aureus (Trayer & Buckley, 1970). Proteinase K is a broad specificity endopeptidase that is used to digest proteins (Gradisar et al., 2005).

16S rRNA gene Amplicon Library Construction. Bacterial profiles were determined by broad-range amplification and sequence analysis of 16S rRNA genes following our previously described methods (Hara et al., 2012; Markle et al., 2013). Amplicons were generated using primers that target approximately 300 base pairs of the V1/V2 variable region of the 16S rRNA gene. Each DNA was amplified in triplicate along with a barcode specific negative PCR control. PCR reactions contained 1X HotMaster Mix (5Prime), 150 nM each PCR primer and template in a reaction volume of 25µl. Cycling conditions were 94 °C denaturation for 120 seconds followed by 30 cycles of 95 °C 20 seconds, 52 °C 20 seconds and 65 °C 60 seconds. Amplification was confirmed using agarose gel electrophoresis. None of the negative PCR controls showed evidence of amplification. PCR products were normalized based on agarose gel densitometry, pooled, lyophilized, purified and concentrated using a DNA Clean and Concentrator Kit (Zymo, Irvine, CA). Pooled amplicons were quantified using Qubit Fluorometer 2.0 (Invitrogen, Carlsbad, CA). The pool was diluted to 4nM and denatured with 0.2 N NaOH at room temperature. The denatured DNA was diluted to 15pM and spiked with 10% of the Illumina PhiX control DNA prior to loading.
the sequencer. Illumina paired-end sequencing was performed on the MiSeq using a 500 cycle version 2 reagent kit.

Analysis of Illumina Paired-end Reads. As previously described, paired-end sequences were sorted by sample via barcodes in the paired reads with a python script (Markle et al., 2013). Sorted paired end sequence data were deposited in the NCBI Short Read Archive under accession number SRP043334. The sorted paired reads were assembled using phrap (Ewing and Green 1998; Ewing et al. 1998.). Pairs that did not assemble were discarded. Assembled sequence ends were trimmed over a moving window of 5 nucleotides until average quality met or exceeded 20. Trimmed sequences with more than 1 ambiguity or shorter than 250 nt were discarded. Potential chimeras identified with Uchime (usearch6.0.203_i86linux32) (Edgar et al., 2011) using the Schloss Silva reference sequences (Schloss & Westcott, 2011) were removed from subsequent analyses. Assembled sequences were aligned and classified with SINA (1.3.0-r23838)(Pruesse, Peplies & Glöckner, 2012) using the 479,726 bacterial sequences in Silva 115NR (Quast et al., 2013) as reference configured to yield the Silva taxonomy. Sequences with identical taxonomic assignments were grouped into Operational taxonomic units (OTUs). This process generated 4,302,223 sequences for 162 samples (average sequence length: 316 nt; average sample size: 26,557 sequences/sample; minimum sample size: 7,527; maximum samples size: 63,105). The median Good’s coverage score was ≥ 99.70% at the rarefaction point of 7,527.

The software package Explicet (v2.10.5, www.explicet.org) (Robertson et al., 2013) was used to calculate rarefied values for diversity measurements.

Statistical Analysis. Shannon-H alpha diversity, evenness, richness and Morisita Horn (MH) beta diversity were calculated in Explicet. MH beta diversity is a measure of similarity between two communities and ranges from 0 (no similarity) to 1 (identical communities).
Principal Coordinate Analysis (PCoA) was used to assess differences at the community level utilizing 1-MH. 1-MH distances were used to show the dissimilarity between with EnzD and without EnzD in PCoA plots instead of MH distances, which are a measure of similarity. Relative abundance (RA) for each genus was calculated by dividing the genera-specific sequence counts by the total number of sequences obtained for each sample. Shannon-H diversity, evenness and richness were compared using a Wilcoxon Signed Rank test. Differences in phyla and genera between EnzD samples versus non-EnzD samples with a median RA of at least 1% were evaluated using Wilcoxon Signed rank test for paired samples. Benjamini-Hochberg corrections were used to account for multiple comparisons (Benjamini & Yekutieli, 2001). Spearman correlations were used to assess associations between MH for paired samples and RA of specific genera from the non-digested sample. Analyses were calculated using R version 3.2.4 Revised (2016-03-16 r70336).

Results

Sample Collection. We analyzed 81 airway samples (39 sputum and 42 OP, Figure S1) collected from 63 patients with cystic fibrosis ranging in age from 1.5 to 24 years (9 to 24 sputum and 1.5 to 23 OP). Half of the subjects were female (51%), the majority of subjects were non-Hispanic white (89%) and 52% of subjects were homozygous F508. The median number of samples collected per subject was 1 and ranged between 1 and 3 samples. Seven samples (9%) were negative for standard CF pathogens by culture (Figure S2).

Changes in individual organisms. Individual taxa were assessed at the phyla and genera level by sample type (OP and Sputum). For OP samples, we observed a significantly lower RA
for the phyla Bacteroidetes, Fusobacteria and Proteobacteria when EnzD was used. *Firmicutes*

and *Actinobacteria* both were detected in higher RA with the use of EnzD. For sputum, the RA

for *Bacteroidetes* and *Proteobacteria* were lower with EnzD (Table 1) consistent with findings in

OP samples (Figure 1A).

Genera with a statistically significantly higher RA following EnzD for OP swabs

consisted of: *Gemella, Streptococcus, Actinomyces, Johnsonella,* and *Rothia.* Genera with a

statistically significantly lower RA for OP swabs consisted of: *Prevotella, Veillonella, Neisseria,*

*Haemophilus, Leptotrichia, Campylobacter, Fusobacterium,* and *Granulicatella.* For these
genera, while the changes are statistically significant, the changes may not be clinically

meaningful. The largest changes in RA (>5%) are seen in *Streptococcus, Prevotella,* and

*Veillonella* (Table 2). *Staphylococcus* was the only genus with a significantly higher RA in

sputum following EnzD. Genera with a statistically significantly lower RA in sputum consisted

of: *Veillonella, Granulicatella, Prevotella,* and *Gemella* (Table 2). The largest estimated change

in RA for sputum samples is attributed to *Staphylococcus* (Table 2). *Gemella* was higher in OP

samples with EnzD while it was lower in sputum samples with EnzD (Figure 1B).

Genera traditionally associated with CF include *Pseudomonas, Staphylococcus,*

*Haemophilus, Stenotrophomonas,* and *Achromobacter*(Zemanick et al., 2015). All of the samples

have low RA for *Achromobacter* and all of the OP samples had low RA for *Pseudomonas* and

*Stenotrophomonas.* In the sputum samples, 11 had low amounts of all CF pathogens, 11 were
dominated by *Staphylococcus,* all of which increased with EnzD, and 3 were dominated mostly

by *Haemophilus.* Of the remaining 14 sputum samples, 3 samples were dominated by

*Stenotrophomonas,* 1 increased, 1 decreased and 1 remained unchanged with EnzD. Eleven

sputum samples had > 5% RA *Pseudomonas* prior to EnzD, the RA increased after EnzD in 6 of
these samples (median 18.7 range 1.1% to 68.4%), in those where RA decreased, the median and
range was -6.1%, -1.2% to 42.0% (Table 3).

**Overall community changes.** The Shannon-H alpha Diversity Index was significantly
lower (p < 0.01) with EnzD in sputum samples (Figure S3) due to higher RA of *Staphylococcus*
resulting in a significantly less even community (Shannon-H, Wilcoxon Signed Rank, p < 0.01).
For OP samples, the Shannon-H alpha Diversity Index was also lower likely due to higher RA of
*Streptococcus* with EnzD, although this result did not reach statistical significance (Shannon-H,
Wilcoxon Signed Rank, p = 0.06). Richness and evenness were also not significantly affected by
EnzD in OP samples. Changes in alpha diversity due to use of EnzD do not necessarily
correspond to changes in microbial community composition as measured using beta diversity
(Figure S4).

**Beta Diversity Changes.** There was less impact of EnzD on community composition in
sputum compared to OP samples as measured by MH beta diversity values for each sample pair.
The majority of the MH values (79.5%) for sputum were greater than 0.8, whereas only 38.1% of
OP samples were above that level. For the OP swabs the lowest MH was 0.4 for sputum samples
the lowest MH was 0.48. The distributions between the two sample types were statistically
different (MH, Wilcoxon Rank Sum, p < 0.01, Figure 2). We further investigated these changes
using the MH distance matrix in Principal Coordinate Analysis (PCoA). OP samples changed
more consistently in ordination space with EnzD (Figure 3A). The consistent changes observed
in the OP samples were largely due to the change in *Streptococcus*, *Gemella*, and *Rothia* (all
Gram-positive) as well as *Neisseria*, *Leptotrichia*, *Prevotella*, and *Veillonella* (Gram-negative);
with the samples undergoing EnzD primarily clustered around *Streptococcus*, *Gemella*, and
*Rothia* (Figure 3A). Findings here align with previously discussed individual level changes in
genera where Gram-positive bacteria were found in significantly higher RA while Gram-negative bacteria was found in significantly lower RA with EnzD (Table 2). As indicated in Figure 3B, sputum samples showed less impact from EnzD, with a large group of samples having limited changes in MH. A subset of the sputum samples demonstrated large changes in MH with EnzD, but with no consistent direction of change as was seen in the OP samples (Figure 3B). Sputum appears to be more heterogeneous compared to OP samples. Sputum was primarily influenced by enhanced extraction of *Staphylococcus, Veillonella,* and *Streptococcus* (Figure 3B). This result is consistent with Table 2 where *Staphylococcus* and *Veillonella* are shown to have a larger change than *Streptococcus*.

**Associations between community composition and MH.** We found no striking evidence of a single phylum or genus whose relative abundance was associated with MH (Figure S5). Combination of Gram-positive bacteria was calculated using the summation of (Actinobacteria + *Firmicutes* (-*Veillonella*)). For the OP samples with large changes in their communities with EnzD, the relative abundance of Gram-positive organisms was lower compared to those samples with limited changes in their communities (Figure 4). For all the OP samples, the relative abundance of Gram-positive organisms was higher with EnzD. There was an association between change in relative abundance of Gram-positive organisms with EnzD and MH values for the pairs (Spearman’s correlation, r = -0.60; p < 0.01; Figure 4B).

**Discussion**

In this work, we demonstrate that EnzD of airway samples changes the bacterial community detected by sequencing primarily due to increased detection of organisms with a Gram-positive cell wall structure. From the biplots (Figure 3A) we can see that for OP samples there is a clear shift in microbial composition between those without EnzD and those with EnzD.
With EnzD the OP samples are highly clustered around \textit{Gemella, Rothia, and Streptococcus} whereas those without EnzD are dispersed around \textit{Neisseria, Prevotella} and \textit{Veillonella}. These observations are consistent with cell wall structure; we would predict that given their rigid cell wall Gram-positive bacteria would drive changes in community composition for those samples with EnzD. \textit{Streptococcus, Gemella, and Rothia} explain a large amount of the variability in the OP samples. \textit{Streptococcus} and \textit{Staphylococcus} are Gram-positive taxa explaining a large amount of the variability in the sputum samples. Among the Gram-negative taxa explaining a large amount of variability in OP and sputum samples are \textit{Neisseria, Veillonella, and Prevotella} due to decreasing relative abundance with EnzD. \textit{Granulicatella}, a member of the Firmicutes had decreased RA with EnzD, which was not consistent with other Gram positive taxa. \textit{Granulicatella} is reported to have pleomorphic and variable Gram stain characteristics, which may explain this observation (Bottone et al., 1995; Christensen & Facklam, 2001).

Difference in OP and sputum samples can be due to differences in the microbial communities which may be related to multiple factors including anatomic location, inter individual variability and disease severity. The samples used in this study were collected for clinical evaluation of airway infection, although separate evaluation for sample adequacy was not performed, these samples are reflective of what is being used to make clinical decisions. The patients that were not capable of expectorating sputum tend to be younger with presumably less lung disease (i.e., fewer pathogens). There are also differences between upper and lower airways (Zemanick et al., 2015) that could also impact the community composition observed.

Willner et al. demonstrated that genera detection varied significantly between 5 commonly used extraction methods with \textit{Staphylococcus} being detected with varying efficiency (Willner et al., 2012). Support for these findings showed the largest difference in microbial
proportions between two DNA extraction methods (Norgen and Qiagen) was found in

*Staphylococcus* (Pérez-Losada et al., 2016). Consistent with previous findings, EnzD revealed a

higher RA of *Staphylococcus* in OP samples. Further, when evaluated in both OP swab and

sputum samples from pediatric subjects with CF, variations in detection of *Staphylococcus* were

observed (Johnson et al., 2016). Total RA for *Staphylococcus* in sputum samples was higher

overall, but had less of a change before and after EnzD (Johnson et al., 2016). Zhao et al. looked

at sputum and saw an increase in *Staphylococcus*, which we corroborate (Zhao et al., 2012). We

also found a higher RA of *Streptococcus* in OP samples. Johnson et al. found that for OP

samples DNA concentration consistently increased with EnzD. This indicates that in addition to

observing changes in RA, EnzD probably better represents the absolute amounts of genera

present in OP samples.

*Limitations.* There are certain limitations to our study. First, only two airway sample

types collected from subjects with CF were evaluated, thus limiting more general inferences

regarding the effects of EnzD in other samples types. However, this study does include OP

samples, which have not previously been evaluated and represents an important sample type in

early CF. The patient’s clinical status at the time of sample collection is unknown, this hampers

our ability to determine whether these samples are reflective of both clinical stability or during a

pulmonary exacerbation. However, because paired samples were used to assess the effect of

EnzD, the difference for each pair in not confounded by clinical status. Because only a single

replicate with and without EnzD was evaluated, we are unable to compare effects due to EnzD

versus technical variability. However, the observation of the consistent differences for the

majority of the sample pairs provides some evidence that the change is due to EnzD rather than
technical variability. In our study we considered beta-diversity values of 0.8 or greater to be within the limits of change due to biological variability.

The utility of EnzD is difficult to predict due to the strong influence of the community composition in any given sample on the results. There is a compelling argument to utilize EnzD in studies that rely on OP swabs as previous studies have shown increased sensitivity for detection of Staphylococcus. While the argument is less compelling for sputum, EnzD should be applied consistently. Other sample types would require evaluation to determine how much impact is observed. However, increasing the RA of any group makes it harder to identify minor components in the community. EnzD could negatively impact the ability to identify low abundance Gram-negative organisms as seen through the decrease in Gram-negative genera shown in Table 2. This includes many important pathogens in CF (e.g. Pseudomonas) and should be considered carefully.

**Conclusions**

In summary, we found that the use of EnzD on airway samples prior to DNA extraction and sequencing alters microbiome community composition results, likely due to improved detection of gram-positive bacterial taxa (e.g. *Streptococcus* and *Staphylococcus*). The use of EnzD appears particularly important for analysis of OP swab samples. EnzD use with sputum samples may be less critical and has the potential to decrease sensitivity for low abundance taxa. Our findings highlight the need for a consistent approach to airway sample processing and analysis, and suggest that EnzD should be applied routinely in studies using OP swabs and studies requiring sensitive detection of *Staphylococcus* and *Streptococcus*. 
References

Armstrong DS., Grimwood K., Carlin JB., Carzino R., Olinsky A., Phelan PD. 1996. Bronchoalveolar Lavage or Oropharyngeal Cultures to Identify Lower Respiratory Pathogens in Infants With Cystic Fibrosis. Pediatric Pulmonology Pediatr Pulmonol 21.

Benjamini Y., Yekutieli D. 2001. THE CONTROL OF THE FALSE DISCOVERY RATE IN MULTIPLE TESTING UNDER DEPENDENCY. The Annals of Statistics 29:1165–1188.

Bottone EJ., Thomas CA., Lindquist D., Janda JM. 1995. Difficulties encountered in identification of a nutritionally deficient streptococcus on the basis of its failure to revert to streptococcal morphology. Journal of clinical microbiology 33:1022–4.

Browder HP., Zygmunt WA., Young JR., Tavormina PA. 1965. Lysostaphin: Enzymatic mode of action. Biochemical and Biophysical Research Communications 19:383–389. DOI: 10.1016/0006-291X(65)90473-0.

Burns JL., Emerson J., Stapp JR., Yim DL., Krzewinski J., Louden L., Ramsey BW., Clausen CR. 1998. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 27:158–63.

Christensen JJ., Facklam RR. 2001. Granulicatella and Abiotrophia species from human clinical specimens. Journal of clinical microbiology 39:3520–3. DOI: 10.1128/JCM.39.10.3520-3523.2001.

Cummings LA., Kurosawa K., Hoogestraat DR., SenGupta DJ., Candra F., Doyle M., Thielges S., Land TA., Rosenthal CA., Hoffman NG., Salipante SJ., Cookson BT. 2016. Clinical
Next Generation Sequencing Outperforms Standard Microbiological Culture for Characterizing Polymicrobial Samples. *Clinical Chemistry* 62.

Edgar RC., Haas BJ., Clemente JC., Quince C., Knight R. 2011. UCHIME improves sensitivity and speed of chimera detection. *Bioinformatics (Oxford, England)* 27:2194–200. DOI: 10.1093/bioinformatics/btr381.

Ewing B., Green P. 1998. Base-Calling of Automated Sequencer Traces Using *Phred*. II. Error Probabilities. *Genome Research* 8:186–194. DOI: 10.1101/gr.8.3.186.

Gradisar H., Friedrich J., Krizaj I., Jerala R. 2005. Similarities and specificities of fungal keratinolytic proteases: comparison of keratinases of Paecilomyces marquandii and *Doratomyces microsporus* to some known proteases. *Applied and environmental microbiology* 71:3420–6. DOI: 10.1128/AEM.71.7.3420-3426.2005.

Hara N., Alkanani AK., Ir D., Robertson CE., Wagner BD., Frank DN., Zipris D. 2012. Prevention of Virus-Induced Type 1 Diabetes with Antibiotic Therapy. *The Journal of Immunology* 189:3805–3814. DOI: 10.4049/jimmunol.1201257.

Heijerman H. 2005. Infection and inflammation in cystic fibrosis: a short review. *Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society* 4 Suppl 2:3–5. DOI: 10.1016/j.jcf.2005.05.005.

Hoppe JE., Towler E., Wagner BD., Accurso FJ., Sagel SD., Zemanick ET. 2015. Sputum induction improves detection of pathogens in children with cystic fibrosis. *Pediatric pulmonology* 50:638–46. DOI: 10.1002/ppul.23150.

Johnson EJ., Zemanick ET., Accurso FJ., Wagner BD., Robertson CE., Harris JK. 2016.
Molecular identification of Staphylococcus aureus in airway samples from children with cystic fibrosis. *PLoS ONE* 11:1–12. DOI: 10.1371/journal.pone.0147643.

LiPuma JJ. 2010. The Changing Microbial Epidemiology in Cystic Fibrosis. *Clinical Microbiology Reviews* 23:299–323. DOI: 10.1128/CMR.00068-09.

Lozupone CA., Stombaugh J., Gonzalez A., Ackermann G., Wendel D., Vazquez-Baeza Y., Jansson JK., Gordon JI., Knight R. 2013. Meta-analyses of studies of the human microbiota. *Genome Research* 23:1704–1714. DOI: 10.1101/gr.151803.112.

Markle JGM., Frank DN., Mortin-Toth S., Robertson CE., Feazel LM., Rolle-Kampczyk U., von Bergen M., McCoy KD., Macpherson AJ., Danska JS. 2013. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. *Science (New York, N.Y.)* 339:1084–8. DOI: 10.1126/science.1233521.

Pérez-Losada M., Crandall K., Freishtat RJ., Pérez-Losada M., Crandall KA. 2016. Comparison of two commercial DNA extraction kits for the analysis of nasopharyngeal bacterial communities. *AIMS Microbiology* 2:108–119. DOI: 10.3934/microbiol.2016.2.108.

Pruesse E., Peplies J., Glöckner FO. 2012. SINA: accurate high-throughput multiple sequence alignment of ribosomal RNA genes. *Bioinformatics (Oxford, England)* 28:1823–9. DOI: 10.1093/bioinformatics/bts252.

Quast C., Pruesse E., Yilmaz P., Gerken J., Schweer T., Yarza P., Peplies J., Glöckner FO. 2013. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. *Nucleic acids research* 41:D590-6. DOI: 10.1093/nar/gks1219.
Robertson CE., Harris JK., Wagner BD., Granger D., Browne K., Tatem B., Feazel LM., Park
K., Pace NR., Frank DN. 2013. Explicet: graphical user interface software for metadata-driven management, analysis and visualization of microbiome data. *Bioinformatics* (Oxford, England) 29:3100–1. DOI: 10.1093/bioinformatics/btt526.

Salazar O., Asenjo JA. 2007. Enzymatic lysis of microbial cells. DOI: 10.1007/s10529-007-9345-2.

Schindler CA., Schuhardt VT. 1964. Lysostaphin: A New Bacteriolytic Agent for the *Staphylococcus*. *Proceedings of the National Academy of Sciences of the United States of America* 51:414–421. DOI: 10.1073/pnas.51.3.414.

Schloss PD., Westcott SL. 2011. Assessing and Improving Methods Used in Operational Taxonomic Unit-Based Approaches for 16S rRNA Gene Sequence Analysis. *Applied and Environmental Microbiology* 77:3219–3226. DOI: 10.1128/AEM.02810-10.

Trayer HR., Buckley CE. 1970. Molecular properties of lysostaphin, a bacteriolytic agent specific for *Staphylococcus aureus*. *The Journal of biological chemistry* 245:4842–6.

Willner D., Daly J., Whiley D., Grimwood K., Wainwright CE., Hugenholtz P., Tringe S., Hugenholtz P. 2012. Comparison of DNA Extraction Methods for Microbial Community Profiling with an Application to Pediatric Bronchoalveolar Lavage Samples. *PLoS ONE* 7:e34605. DOI: 10.1371/journal.pone.0034605.

Wolter DJ., Emerson JC., McNamara S., Buccat AM., Qin X., Cochrane E., Houston LS., Rogers GB., Marsh P., Prehar K., Pope CE., Blackledge M., Deziel E., Bruce KD., Ramsey BW., Gibson RL., Burns JL., Hoffman LR. 2013. *Staphylococcus aureus* Small-Colony Variants Are Independently Associated With Worse Lung Disease in Children With Cystic Fibrosis.
Clinical Infectious Diseases 57:384–391. DOI: 10.1093/cid/cit270.

Yuan S., Cohen DB., Ravel J., Abdo Z., Forney LJ. 2012b. Evaluation of Methods for the Extraction and Purification of DNA from the Human Microbiome. PLoS ONE 7:e33865. DOI: 10.1371/journal.pone.0033865.

Zemanick ET., Wagner BD., Harris JK., Wagoner JS., Accurso FJ., Sagel SD. 2010. Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures. Pediatric pulmonology 45:569–77. DOI: 10.1002/ppul.21221.

Zemanick ET., Wagner BD., Robertson CE., Stevens MJ., Szefer SJ., Accurso FJ., Sagel SD., Harris JK. 2015. Assessment of Airway Microbiota and Inflammation in Cystic Fibrosis Using Multiple Sampling Methods. Annals of the American Thoracic Society 12:221–229. DOI: 10.1513/AnnalsATS.201407-310OC.

Zhao J., Carmody LA., Kalikin LM., Li J., Petrosino JF., Schloss PD., Young VB., LiPuma JJ. 2012. Impact of enhanced Staphylococcus DNA extraction on microbial community measures in cystic fibrosis sputum. PloS one 7:e33127. DOI: 10.1371/journal.pone.0033127.
**Table 1** (on next page)

Table 1

Median relative abundance in EnzD and Non-EnzD groups; estimated change (EnzD – Non-EnzD) in median RA by Phyla.
| Phyla        | EnzD % | Non-EnzD % | Estimated change in RA % | P-Value | Corrected p-Value |
|--------------|--------|------------|--------------------------|---------|------------------|
| Actinobacteria | 5.60   | 1.25       | 3.79                     | <0.01   | <0.01            |
| Bacteroidetes  | 7.80   | 19.35      | -12.73                   | <0.01   | <0.01            |
| Firmicutes    | 68.31  | 48.32      | 16.78                    | <0.01   | <0.01            |
| Fusobacteria  | 3.50   | 8.83       | -1.97                    | <0.01   | <0.01            |
| Proteobacteria | 2.88   | 7.71       | -5.52                    | <0.01   | <0.01            |

| Phyla        | EnzD % | Non-EnzD % | Estimated change in RA % | P-Value | Corrected p-Value |
|--------------|--------|------------|--------------------------|---------|------------------|
| Actinobacteria | 0.03   | 0.01       | 1.12                     | 0.06    | 0.06             |
| Bacteroidetes  | 0.01   | 0.06       | -3.52                    | <0.01   | <0.01            |
| Firmicutes    | 0.84   | 0.72       | 4.77                     | 0.08    | 0.08             |
| Proteobacteria | 0.01   | 0.02       | -1.36                    | <0.01   | <0.01            |
**Table 2** *(on next page)*

Table 2

Median relative abundance in EnzD and Non-EnzD groups; estimated change (EnzD- Non-EnzD); in Median RA by Genera.
| Genera     | EnzD % | Non-EnzD % | Estimated change in RA % | P-Value  | Corrected p-Value |
|------------|--------|------------|--------------------------|----------|-------------------|
| Streptococcus | 36.51  | 14.81      | 21.75                    | <0.01    | <0.01             |
| Prevotella  | 6.62   | 16.20      | -10.90                   | <0.01    | <0.01             |
| Veillonella | 9.27   | 19.22      | -7.86                    | <0.01    | <0.01             |
| Neisseria   | 0.72   | 1.94       | -3.62                    | <0.01    | <0.01             |
| Actinomyces | 2.93   | 0.73       | 2.50                     | <0.01    | <0.01             |
| Granulicatella | 1.80 | 2.44       | -0.62                    | <0.01    | <0.01             |
| Gemella     | 1.89   | 0.64       | 1.23                     | <0.01    | <0.01             |
| Leptotrichia | 1.16  | 3.79       | -1.44                    | <0.01    | <0.01             |
| Fusobacterium | 1.47 | 3.08       | -0.56                    | <0.01    | <0.01             |
| Rothia      | 1.70   | 0.27       | 1.25                     | <0.01    | <0.01             |
| Haemophilus | 0.45   | 1.69       | -0.91                    | <0.01    | <0.01             |
| Johnsonella | 0.97   | 0.40       | 1.19                     | <0.01    | <0.01             |
| Campylobacter | 0.50 | 0.75       | -0.25                    | <0.01    | <0.01             |

| Genera     | EnzD % | Non-EnzD % | Estimated change in RA % | P-Value  | Corrected p-Value |
|------------|--------|------------|--------------------------|----------|-------------------|
| Streptococcus | 27.85  | 22.48      | 1.33                     | 0.50     | 0.50              |
| Staphylococcus | 1.39   | 0.62       | 5.47                     | <0.01    | <0.01             |
| Prevotella  | 0.88   | 3.54       | -1.91                    | <0.01    | <0.01             |
| Veillonella | 1.09   | 6.01       | -3.55                    | <0.01    | <0.01             |
| Granulicatella | 0.53 | 1.77       | -1.30                    | <0.01    | <0.01             |
| Gemella     | 0.53   | 1.68       | -0.62                    | <0.01    | 0.02              |
| Rothia      | 0.84   | 0.57       | 0.21                     | 0.24     | 0.27              |
**Table 3** (on next page)

Table 3

Displays the RA for CF pathogens detected in each sample. Samples are highlighted when the difference in relative abundance was at least 1%, red for increase with EnzD and blue with a decrease. The grey rows indicate the median (min, max) for the difference in relative abundance for the highlighted samples.
| Staphylococcus | Achromobacter | Haemophilus | Stenotrophomonas | Pseudomonas |
|---------------|---------------|-------------|------------------|-------------|
| Non EnzD      | EnzD          | Non EnzD    | EnzD             | Non EnzD    | EnzD         | Non EnzD    | EnzD             |
| OP1           | 0              | 0.01%       | 0                | 1.63%       | 0.34%        | 0           | 0                | 0              |
| OP2           | 0              | 0.08%       | 0                | 4.03%       | 1.56%        | 0           | 0                | 0              |
| OP3           | 0.01%          | 0.07%       | 0                | 0.04%       | 0            | 0           | 0                | 0              |
| OP4           | 0.01%          | 0.03%       | 0                | 1.96%       | 0.56%        | 0           | 0                | 0              |
| OP5           | 0.01%          | 0.04%       | 0                | 2.65%       | 0.83%        | 0           | 0                | 0              |
| OP6           | 0              | 0.01%       | 0                | 0.00%       | 0.01%        | 0           | 0.01%           | 0              |
| OP7           | 0              | 0          | 0                | 5.71%       | 1.46%        | 0           | 0                | 0              |
| OP8           | 0.15%          | 1.13%       | 0                | 2.05%       | 0.65%        | 0           | 0                | 0              |
| OP9           | 0              | 0.02%       | 0                | 15.12%      | 7.11%        | 0           | 0                | 0              |
| OP10          | 0              | 0.04%       | 0                | 0.25%       | 0.08%        | 0           | 0                | 0              |
| OP11          | 0.01%          | 0.03%       | 0                | 5.86%       | 2.03%        | 0           | 0                | 0              |
| OP12          | 0.02%          | 0.03%       | 0                | 0.21%       | 0.11%        | 0           | 0.01%           | 0.02%          |
| OP13          | 0.08%          | 0.30%       | 0                | 1.19%       | 0.22%        | 0.01%       | 0                | 0              |
| OP14          | 0.06%          | 0.37%       | 0                | 2.41%       | 1.43%        | 0           | 0                | 0.03%          |
| OP15          | 0.07%          | 1.02%       | 0                | 0.03%       | 0.04%        | 0           | 0.01%           | 0.01%          |
| OP16          | 0.04%          | 0.05%       | 0                | 0.09%       | 0.02%        | 0           | 0                | 0              |
| OP17          | 0.01%          | 0.08%       | 0                | 0.57%       | 0.31%        | 0           | 0                | 0              |
| OP18          | 0.01%          | 0.01%       | 0                | 3.49%       | 1.87%        | 0           | 0.01%           | 0.01%          |
| OP19          | 0.01%          | 0.57%       | 0                | 1.91%       | 0.57%        | 0           | 0                | 0.01%          |
| OP20          | 0              | 0          | 0                | 3.45%       | 1.79%        | 0           | 0                | 0              |
| OP21          | 0.02%          | 0.10%       | 0                | 0.40%       | 0.18%        | 0           | 0.01%           | 0.02%          |
| OP22          | 0              | 0          | 0                | 0.35%       | 0.05%        | 0           | 0.01%           | 0.05%          |
| OP23          | 0.07%          | 0.18%       | 0                | 11.95%      | 7.84%        | 0.01%       | 0                | 0.01%          |
| OP24          | 0              | 0          | 0                | 0.17%       | 0.03%        | 0           | 0                | 0              |
| OP25          | 0.01%          | 0.01%       | 0                | 0.23%       | 0.07%        | 0.01%       | 0.01%           | 0.02%          |
| OP26          | **2.17%**      | **3.92%**   | 0                | **0.45%**   | **0.04%**    | 0           | 0                | **0.01%**      |
| OP27          | **0.11%**      | **0.16%**   | 0                | 0           | 0.00%        | 0           | 0                | **0.01%**      |
| OP28          | 0.05%          | 0          | 0                | 2.44%       | 1.82%        | 0           | 0                | 0              |
| OP29          | 0              | 0          | 0                | 1.75%       | 0.67%        | 0.05%       | 0.03%           | 0              |
| OP30          | 0.01%          | 0.03%       | 0                | 40.38%      | 30.81%       | 0           | 0                | 0              |
| OP31          | 0              | 0          | 0                | 0.61%       | 0.14%        | 0           | 0                | 0              |
| OP32          | 0.01%          | 0.01%       | 0                | 3.40%       | 1.09%        | 0           | 0.07%           | 0.06%          |
| OP33          | 0              | 0          | 0                | 0.30%       | 0.04%        | 0           | 0                | 0              |
| OP34          | **3.34%**      | **14.25%**  | 0                | **2.01%**   | **1.19%**    | 0           | 0                | **0.01%**      |
| OP35          | 0.05%          | 0.08%       | 0                | 4.44%       | 4.27%        | 0           | 0                | 0              |
| OP36          | 0.02%          | 0.22%       | 0                | 0.03%       | 0.01%        | 0           | 0                | 0              |
| OP37          | 0.11%          | 0.19%       | 0                | 2.06%       | 0.58%        | 0           | 0                | 0              |
| OP38          | 0.01%          | 0.04%       | 0                | 3.68%       | 1.54%        | 0           | 0                | 0              |
| OP39          | 0.06%          | 0.07%       | 0                | 0           | 0           | 0           | 0.01%           | 0              |
| OP40          | 0.13%          | 0.11%       | 0                | 0.01%       | 0           | 0           | 0.01%           | 0.02%          |
|  | OP41 | 0.05%  | 0.03% | 0  | 0 | 1.91% | 1.20% | 0  | 0 | 0 | 0  | 0  | 0  |
|  | OP42 | 0.01%  | 0.01% | 0  | 0 | 0.05% | 0.01% | 0  | 0 | 0 | 0.02% | 0.01% |
|  | 6.3 (1.8, 10.9) | - | -1.8 (-1.1, -9.6) | - | - |
| Staphylococcus | Achromobacter | Haemophilus | Stenotrophomonas | Pseudomonas |
| Non EnzD | EnzD | Non EnzD | EnzD | Non EnzD | EnzD | Non EnzD | EnzD | Non EnzD | EnzD |
| Sputum | |
| ES1 | 2.24% | 1.99% | 0 | 0 | 0 | 0 | 0 | 0 | 0.66% | 0.51% |
| ES2 | 0.01% | 0.05% | 0 | 0 | 2.89% | 2.79% | 0 | 0 | 39.12% | 79.91% |
| ES3 | 0 | 0 | 0 | 0 | 8.77% | 0.83% | 0 | 0 | 0 | 0.01% |
| ES4 | 0.05% | 0.12% | 0 | 0 | 9.52% | 6.47% | 0 | 0 | 1.27% | 1.02% |
| ES5 | 34.61% | 72.13% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01% |
| ES6 | 43.91% | 84.67% | 0 | 0 | 0.01% | 0 | 0 | 0 | 5.04% | 1.39% |
| ES7 | 89.38% | 97.47% | 0 | 0 | 0 | 0 | 0.07% | 0.02% | 0.01% | 0 |
| ES8 | 16.72% | 32.21% | 0 | 0 | 0 | 0 | 0 | 0 | 52.01% | 9.96% |
| ES9 | 0.49% | 6.75% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01% |
| ES10 | 26.05% | 11.45% | 0 | 0 | 1.08% | 0.72% | 0 | 0 | 10.88% | 3.89% |
| ES11 | 31.47% | 96.31% | 0 | 0 | 4.11% | 0.23% | 0.14% | 0.02% | 0.01% | 0 |
| ES12 | 0.04% | 0.04% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ES13 | 26.05% | 11.45% | 0 | 0 | 1.08% | 0.72% | 0 | 0 | 31.81% | 58.28% |
| ES14 | 0.06% | 0.13% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.02% | 0.03% |
| ES15 | 16.08% | 29.44% | 0 | 0 | 11.39% | 7.50% | 0 | 0 | 13.04% | 14.15% |
| ES16 | 67.38% | 86.70% | 0 | 0 | 0 | 0 | 0 | 0 | 1.69% | 0.88% |
| ES17 | 89.38% | 97.47% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01% |
| ES18 | 0.03% | 0.05% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ES19 | 62.05% | 11.45% | 0 | 0 | 6.75% | 2.09% | 11.95% | 12.85% | 0.01% | 0 |
| ES20 | 0.49% | 6.75% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ES21 | 0.01% | 0.01% | 0 | 0 | 0 | 0 | 0 | 0 | 56.44% | 37.37% | 0 | 0 |
| ES22 | 1.08% | 1.31% | 0 | 0 | 6.74% | 8.94% | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ES23 | 0.07% | 0.34% | 0 | 0 | 0.01% | 0 | 0 | 0 | 0 | 0 | 16.08% | 0.23% |
| ES24 | 0.07% | 0.15% | 0 | 0 | 0.60% | 0.28% | 0.01% | 0 | 87.24% | 81.12% |
| ES25 | 0 | 0 | 0 | 0 | 1.18% | 0.41% | 2.41% | 1.51% | 0 | 0 |
| ES26 | 41.52% | 87.96% | 0 | 0 | 5.60% | 0.64% | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ES27 | 64.41% | 97.56% | 0 | 0 | 0.43% | 0.02% | 2.93% | 0.11% | 0 | 0 |
| ES28 | 0.02% | 0.04% | 0 | 0 | 0.01% | 0 | 0.01% | 0.04% | 0.02% | 0.01% |
| ES29 | 73.98% | 98.00% | 0.01% | 0 | 0 | 0 | 0 | 0 | 0.05% | 0.01% |
| ES30 | 67.38% | 86.70% | 0 | 0 | 0 | 0 | 0 | 0 | 0.18% | 0.14% |
| ES31 | 90.32% | 96.74% | 0 | 0 | 0 | 0 | 0.01% | 0.01% | 0 | 0 |
| ES32 | 0.02% | 0.01% | 0 | 0 | 0.02% | 0 | 33.62% | 57.14% | 0.07% | 0.04% |
| ES33 | 49.36% | 78.78% | 0 | 0 | 0 | 0 | 0.07% | 0 | 0.03% | 0.06% |
| ES34 | 0.05% | 0.15% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.03% |
| ES35 | 1.84% | 7.29% | 0 | 0 | 0.66% | 0.40% | 0.17% | 0.10% | 22.94% | 21.79% |
| ES36 | 0.30% | 0.16% | 0 | 0 | 0.32% | 0.02% | 0.01% | 0.02% | 28.07% | 96.42% |
| ES37 | 0 | 0 | 0 | 0 | 1.90% | 1.22% | 0 | 0 | 0.18% | 0.31% |
Figure 1

Figure 1. Boxplots for individual taxa that change within paired samples. The distribution of differences in paired samples is shown for phyla (A) and genera (B). Taxa with limited differences between the paired samples are tightly distributed around zero, and those with increased relative abundance after EnzD have positive distributions. Note the median RA for Fusobacteria in sputum is less than 1%. P-values correspond to Benjamini-Hochberg corrected Wilcoxon Signed rank test for paired samples.
Figure 2

Boxplots showing distribution of Morisita-Horn (MH) similarity metric for paired samples in OP and sputum. Wilcoxon rank sum tests indicate the distributions between the two sample types were statistically different (Benjamini-Hochberg corrected p<0.01). The MH metric ranges from 0-1 with a value of 1 indicating identical communities, and 0 indicating no overlap between communities. The line indicates the median value and the box ranges from the 25th and 75th percentiles, the whiskers extend to 1.5 times the interquartile range.
Figure 3

Figure 3. Ordination biplot, using 1-MH beta diversity values for OP (A) and sputum (B). Values closer together are more similar. Paired samples are connected with a line, vectors for the genera with at least 1% RA and p<0.005 (by permutation test) for R^2 of the loading.
Figure 4

A) Scatterplot of relative abundance of Gram-positive taxa in non-EnzD samples versus Morisita-Horn (MH) similarity metric of paired samples. MH metric ranges from 0-1 with a value of 1 indicating identical communities, and 0 indicating no overlap between communities. OP samples are shown in red and sputum in blue. B) Scatterplot of the difference in relative abundance of Gram-positive taxa versus MH of paired samples OP samples are shown in red and sputum in blue.